Performance of Several Method-of-Characteristics Exhaust Nozzles

Nozzle performance data were obtained with three "method-of-characteristics" nozzles and a 150 conical nozzle at pressure ratios up to 130. Each basic configuration was cut off and tested at expansion ratios of 25, 20, 15, and 10. Unheated dry air was used at nozzle inlet pressures up to 22,000 pounds per square foot absolute. Nozzle thrust data were extrapolated to infinite pressure ratio (zero discharge pressure). As much as 1-percent increase in thrust with no increase in nozzle surface area (weight), can be obtained by using a method-of-characteristics, nozzle instead of a 15 conical nozzle when operating with a nozzle expansion ratio of 25 and nozzle pressure ratios from 200 to infinity. Conversely, for the same thrust, reductions in nozzle divergent surface area in the order of 25 percent are possible. The thrust performance of the method-of-characteristics nozzle was not as good as that of the 150 conical nozzle when operating at pressure ratios considerably below design (below 100 for the expansion ratio 25 nozzles). Theoretical and measured nozzle momentum coefficients agreed within about 0.6 percent. This is the order of accuracy of both the measured and theoretical values

Dynamic stretching is effective as static stretching at increasing flexibility

This study examined the effect of dynamic and static (standard) stretching on hamstring flexibility. Twenty-five female volleyball players were randomly assigned to dynamic (n = 12) and standard (n = 13) stretching groups. The experimental group trained with repetitive dynamic stretching exercises, while the standard modality group trained with static stretching exercises. The stretching interventions were equivalent in the time at stretch and were performed three days a week for four weeks. Both stretching groups showed significant improvements (P < .001) in range of motion (ROM) during the intervention. However, no difference in gains in the range of motion between stretching groups was observed. It was concluded that both dynamic stretching and standard stretching are effective at increasing ROM

Transcription factor Pebbled/RREB1 regulates injury-induced axon degeneration

Genetic studies of Wallerian degeneration have led to the identification of signaling molecules (e.g., dSarm/Sarm1, Axundead, and Highwire) that function locally in axons to drive degeneration. Here we identify a role for the Drosophila C2H2 zinc finger transcription factor Pebbled [Peb, Ras-responsive element binding protein 1 (RREB1) in mammals] in axon death. Loss of Peb in Drosophila glutamatergic sensory neurons results in either complete preservation of severed axons, or an axon death phenotype where axons fragment into large, continuous segments, rather than completely disintegrate. Peb is expressed in developing and mature sensory neurons, suggesting it is required to establish or maintain their competence to undergo axon death. peb mutant phenotypes can be rescued by human RREB1, and they exhibit dominant genetic interactions with dsarm mutants, linking peb/RREB1 to the axon death signaling cascade. Surprisingly, Peb is only able to fully block axon death signaling in glutamatergic, but not cholinergic sensory neurons, arguing for genetic diversity in axon death signaling programs in different neuronal subtypes. Our findings identify a transcription factor that regulates axon death signaling, and peb mutant phenotypes of partial fragmentation reveal a genetically accessible step in axon death signaling

Evidence for an extensive hydrothermal plume in the Tonga-Fiji region of the South Pacific

Author Posting. © American Geophysical Union, 2004. This article is posted here by permission of American Geophysical Union for personal use, not for redistribution. The definitive version was published in Geochemistry Geophysics Geosystems 5 (2004): Q01003, doi:10.1029/2003GC000607.Several hydrographic stations in the vicinity of the Samoa Islands have 3He/4He above the regional background in the depth range of 1500–1800 m, indicating injection of mantle helium from a local hydrothermal source. The highest δ(3He) = 43.4% was detected at 1726-m depth at 15.0°S, 173.1°W in the bathymetric gap between the Samoa Islands and the northern end of the Tonga-Kermadec Arc. The δ(3He) profile at this station decreases to δ(3He) = 26% at 2500-m depth. The relatively shallow depth of the maximum hydrothermal signal suggests a source different from the conventional Pacific basin helium plume centered at 2500 m that is carried westward from the East Pacific Rise. Stations to the west of this locality show a progressive decrease in the maximum δ(3He) values in the depth range of 1480–1790 m out to 169°E. Stations east of the Tonga-Fiji region show lower 3He values (<26%) at 1700 m and the profiles are dominated by a deeper maximum at 2500 m, presumably the distal traces of hydrothermal input from East Pacific Rise. This pattern in the 3He distribution suggests that the 1700-m deep helium plume is carried in a northwesterly direction some 2000 km from its source near the northern end of the Tonga-Kermadec Arc. At this time very little is known about the source of this hydrothermal plume or the details of its areal extent. Numerous seamounts and rift zones in the region are possible hydrothermal sources for the plume. The summit crater of Vailulu'u, a young seamount at the eastern end of the Samoa chain, was recently discovered to be hydrothermally active at ∼600 m depth [Hart et al., 2000]. However this shallow hydrothermal field on Vailulu'u is an unlikely source for the deeper 1700-m signal. The most likely source would appear to be the extensional zones of the northern Lau Basin system, such as the Mangatolo Triple Junction. Just as the helium plume emanating from Lo'ihi has helped our understanding of the circulation near the Hawaiian Islands [Lupton, 1996], this helium plume in the Tonga-Fiji region has great potential for delineating circulation in this area of the south Pacific.This work was supported by the NOAA Vents Program and by Grants OCE91-05884, OCE92-96237, OCE92-96169, and OCE98-20132 of the Ocean Sciences Division of the National Science Foundation

1964: Abilene Christian College Bible Lectures - Full Text

LEADERSHIP IN THE CHURCH” Being the Abilene Christian College Annual Bible Lectures 1964 Price: $3.95 Published by ABILENE CHRISTIAN COLLEGE STUDENTS EXCHANGE ACC Station Abilene, Texa

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomised, open-label phase 2/3 trial

BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma. METHODS: This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m(2) by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m(2) by body surface area once every 4 weeks; intravenous topotecan 4 mg/m(2) by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, and is active but not recruiting. FINDINGS: Between Feb 27, 2014, and April 10, 2018, 260 patients were enrolled and randomly assigned to the trametinib group (n=130) or the standard-of-care group (n=130). At the primary analysis, there were 217 progression-free survival events (101 [78%] in the trametinib group and 116 [89%] in the standard-of-care group). Median progression-free survival in the trametinib group was 13·0 months (95% CI 9·9–15·0) compared with 7·2 months (5·6–9·9) in the standard-of-care group (hazard ratio 0·48 [95% CI 0·36–0·64]; p<0·0001). The most frequent grade 3 or 4 adverse events in the trametinib group were skin rash (17 [13%] of 128), anaemia (16 [13%]), hypertension (15 [12%]), diarrhoea (13 [10%]), nausea (12 [9%]), and fatigue (ten [8%]). The most frequent grade 3 or 4 adverse events in the standard-of-care group were abdominal pain (22 [17%]), nausea (14 [11%]), anaemia (12 [10%]), and vomiting (ten [8%]). There were no treatment-related deaths. INTERPRETATION: Trametinib represents a new standard-of-care option for patients with recurrent low-grade serous carcinoma. FUNDING: NRG Oncology, Cancer Research UK, Target Ovarian Cancer, and Novartis

Observation of two new Ξb−\Xi_b^- baryon resonances

Two structures are observed close to the kinematic threshold in the $\Xi_b^0 \pi^-$ mass spectrum in a sample of proton-proton collision data, corresponding to an integrated luminosity of 3.0 fb$^{-1}$ recorded by the LHCb experiment. In the quark model, two baryonic resonances with quark content $bds$ are expected in this mass region: the spin-parity $J^P = \frac{1}{2}^+$ and $J^P=\frac{3}{2}^+$ states, denoted $\Xi_b^{\prime -}$ and $\Xi_b^{*-}$. Interpreting the structures as these resonances, we measure the mass differences and the width of the heavier state to be $m(\Xi_b^{\prime -}) - m(\Xi_b^0) - m(\pi^{-}) = 3.653 \pm 0.018 \pm 0.006$ MeV$/c^2$, $m(\Xi_b^{*-}) - m(\Xi_b^0) - m(\pi^{-}) = 23.96 \pm 0.12 \pm 0.06$ MeV$/c^2$, $\Gamma(\Xi_b^{*-}) = 1.65 \pm 0.31 \pm 0.10$ MeV, where the first and second uncertainties are statistical and systematic, respectively. The width of the lighter state is consistent with zero, and we place an upper limit of $\Gamma(\Xi_b^{\prime -}) < 0.08$ MeV at 95% confidence level. Relative production rates of these states are also reported.Comment: 17 pages, 2 figure

Bose-Einstein correlations of same-sign charged pions in the forward region in pp collisions at √s=7 TeV

Bose-Einstein correlations of same-sign charged pions, produced in protonproton collisions at a 7 TeV centre-of-mass energy, are studied using a data sample collected by the LHCb experiment. The signature for Bose-Einstein correlations is observed in the form of an enhancement of pairs of like-sign charged pions with small four-momentum difference squared. The charged-particle multiplicity dependence of the Bose-Einstein correlation parameters describing the correlation strength and the size of the emitting source is investigated, determining both the correlation radius and the chaoticity parameter. The measured correlation radius is found to increase as a function of increasing charged-particle multiplicity, while the chaoticity parameter is seen to decreas